Executive Summary
•PG is a defensive staples compounder trading at a discount to its own history: 21.5x NTM P/E versus a 2 year average of 24.8x (-13%, -0.3 SD), with the de rating driven by stalled organic growth rather than margin or balance sheet deterioration.
•The core problem is volume: FY26 net sales grew +3%, but that was +2% FX and +1% pricing with volume and mix flat, so organic growth of ~1% is the weakest in years and the entire re rating case rests on a volume inflection.
•Quality remains elite: 50.9% gross margin, 22.1% operating margin, 30.3% ROE, and a ~$15b FY26 cash return plan (~$10b dividends plus ~$5b buybacks), which underpins the downside floor near $140.
•Consensus is modestly constructive (28 Buy / 24 Hold / 1 Sell, median target $163.50), but insider selling and heavy 13F reductions suggest institutions are waiting for a volume catalyst before adding.
Financial Snapshot
•Revenue (TTM): $87.03b (+3% YoY)
•Revenue (FY26 reported): $87.0b, comprised of +2% FX, +1% pricing, 0% volume/mix
•Q1 FY26 revenue: $22.39b, net income $4.75b
•Q2 FY26 revenue: $22.21b, net income $4.32b
•Q3 FY26 revenue: $21.23b, net income $3.93b
•Q4 FY26 revenue: $21.20b, net income $3.04b
•Q1 FY26 adjusted EPS: $1.99 (+3% YoY), beat consensus of $1.90
•Gross margin: 50.9%
•Operating margin: 22.1%
•Net margin: 18.4%
•ROE: 30.3%
•Debt/Equity: 64.5%
•Dividend yield: ~2.8%
Forward Outlook
•NTM revenue estimate: $88.78b (+2.9% YoY), implying consensus already bakes in a modest organic reacceleration
•FY+2 revenue estimate: $91.33b, roughly +3% off the NTM base
•NTM EPS estimate: $6.97 consensus, with the latest revision snapshot at $7.08, a modest upward drift
•Forward EPS growth: +5.9%, ahead of revenue growth and reliant on buyback driven share count reduction
•FY+2 EPS estimate: $7.39, implying a ~6% EPS CAGR
•Margin trajectory: gross margin pressure from tariffs and commodity costs, partially offset by pricing and premium mix
•Cash return guidance: ~$10b dividends plus ~$5b buybacks, ~$15b total in FY26
•FX: FY26 benefited from a +2% FX tailwind; sustainability into FY27 is Not disclosed and is a key EPS bridge swing factor
Valuation Analysis
•Current price: $152.83 (as of 2026-10-13)
•TTM P/E: ~22.8x
•NTM P/E: 21.5x (vs 2 year average 24.8x, -13%, -0.3 SD)
•NTM P/S: 4.0x
•NTM EV/EBIT: 17.2x (vs 2 year average 20.5x, -16%, -0.6 SD)
•NTM EV/EBITDA: 15.0x (vs 2 year average 16.2x, -8%, -0.4 SD)
•NTM EV/Rev: 4.3x (vs 2 year average 4.0x, +6%, +0.4 SD)
•LF P/BV: 6.7x (vs 2 year average 5.4x, +23%, +0.6 SD)
•PEG: ~3.7x on 5.9% forward EPS growth, expensive on a growth adjusted basis
•Fair value on P/E reversion to 2 year average: $176.17
•Fair value on EV/EBIT reversion: $184.54
•Fair value on EV/EBITDA reversion: $166.49
•Fair value on EV/Rev reversion: $143.06
•Fair value on P/BV reversion: $124.48
•Blended fair value: ~$165 to $170, reflecting earnings based reversion tempered by weak volume and a rich book value multiple
•Sell side consensus target: $160.13 (median $163.50, range $149 to $172)
Peer Comparison
•CL: ~35.3x TTM P/E, $71.5b market cap, premium multiple on slower growth, oral and personal care overlap
•UL: ~12.7x TTM P/E, $134.9b market cap, deep value on restructuring and EM exposure
•KMB: ~19.2x TTM P/E, $32.3b market cap, closest valuation comp on lower quality growth
•CHD: ~31.9x TTM P/E, $23.6b market cap, premium on higher growth and M&A optionality
•PG: ~22.8x TTM P/E, 21.5x NTM P/E, mid pack on valuation but top tier on margin and scale
Key Risks & Catalysts
Risks
•Zero volume growth: FY26 organic growth of ~1% was entirely pricing, and pricing pushback or private label share gains risk a negative organic print
•China and US share pressure in Beauty (SK-II) and Fabric & Home, where premium skincare demand has softened and competitive intensity is rising
•Gross margin compression from tariffs and commodity costs that pricing may not fully offset
•FX reversal: the +2% FY26 tailwind could swing to a headwind in FY27, pressuring reported revenue and the EPS bridge
•Insider selling: 3 open market sells and 0 buys over 90 days, net -$1.24m, including the CFO selling 3,914 shares at $145.34
•Institutional distribution: 215 holders (-3,932 QoQ), with 106 reduced and 3,841 closed positions, signalling waning conviction
•Rich book value multiple (6.7x vs 5.4x average) leaves valuation exposed if ROE compresses
Catalysts
•Volume inflection in Fabric & Home and Baby care on Pampers premiumization and innovation led mix
•SK-II recovery in China and Beauty segment reacceleration on premium skincare restocking
•Gillette premiumization and grooming innovation driving mix uplift
•Sustained ~$15b annual cash return supporting EPS and a valuation floor
•Multiple reversion toward 2 year averages, worth $14 to $32 per share on P/E and EV/EBIT
•Further analyst upgrades (Evercore ISI upgraded to Outperform on 2026-10-06) if organic growth stabilises
Investment Thesis
PG is a high quality defensive compounder with elite margins (22.1% operating, 18.4% net), 30.3% ROE, and a reliable ~$15b annual cash return, now trading at a genuine discount to its own history at 21.5x NTM P/E versus a 24.8x two year average. The de rating is rational: organic growth has stalled at ~1% with zero volume contribution, and until volume inflects the multiple is unlikely to fully normalise. The bull case is a volume led recovery in Fabric & Home, Pampers premiumization, and an SK-II rebound in China, each of which would re rate the stock toward the $176 to $184 implied by P/E and EV/EBIT reversion.
The bear case is that flat volume, tariff and commodity driven gross margin pressure, and a potential FX reversal keep organic growth in the low single digits, capping upside and leaving the stock range bound. Insider selling and heavy institutional reductions reinforce near term caution, and the rich 6.7x book value multiple offers little cushion if ROE slips.
We rate PG a modest Buy with a 12 month price target of $165, roughly +8% upside plus a ~2.8% dividend for ~11% total return, in line with the consensus median of $163.50 and consistent with our $165 to $170 blended fair value. The thesis hinges on a volume inflection over the next two to three quarters; absent that, the stock likely trades sideways between $140 and $160. Accumulate on weakness toward the $140 to $145 support zone, and treat any confirmed return to positive volume growth as the trigger to add.
